ENDRA Life Sciences (NASDAQ: NDRA) — Perfil da empresa, notícias e dados financeiros
ENDRA Life Sciences enhances ultrasound technology for cost-effective, portable imaging to improve global health.
ENDRA Life Sciences
ENDRA Life Sciences (NASDAQ:NDRA) is a pioneering company focused on enhancing the capabilities of ultrasound technology to solve complex health problems. At its core, ENDRA aims to develop and commercialize Thermo Acoustic Enhanced UltraSound (TAEUS), a technology designed to provide clinicians with the ability to visualize tissue function and composition in ways previously possible only with CT or MRI, but at a fraction of the cost and with portability. This innovative approach opens new possibilities in diagnosing and monitoring diseases by making high-quality imaging more accessible and convenient. With projects spanning from early-stage clinical trials to partnerships aimed at integrating TAEUS into existing medical imaging workflows, ENDRA's objective is clear: to improve global health by making advanced imaging technology more affordable and widespread.
Resumo
Operações
Produtos e/ou serviços de ENDRA Life Sciences
- Development of TAEUS technology to assess non-alcoholic fatty liver disease (NAFLD) via ultrasound, providing a non-invasive, cost-effective diagnostic tool.
- Research into expanding TAEUS applications beyond NAFLD, targeting liver disease diagnostics and potentially other organ assessment.
- Partnerships with medical institutions and liver centers to conduct clinical studies, enhancing TAEUS validation and adoption.
- Collaboration with healthcare and technology companies to integrate TAEUS technology into existing ultrasound systems, broadening market reach.
- Efforts to secure regulatory approvals in key global markets, ensuring TAEUS meets international healthcare standards and requirements.
- Outreach and educational programs for healthcare professionals to increase awareness and understanding of TAEUS technology, supporting its clinical uptake.
equipe executiva do ENDRA Life Sciences
- Alexander Y. TokmanCEO & Chairman
- Richard JacrouxCFO & Secretary
- Jonathan BehrCo-Founder
- Scott SoberHead of Operations
- Ziad RouagHead of Regulatory & Clinical Affairs
- Idan SteinbergHead of Engineering
Principais indicadores financeiros
Resultados divulgados pela ENDRA Life Sciences, em USD.
- Cap. de mercado
- 7,1 mi
- Receita (TTM)
- 0
- P/L
- —
- LPA (diluído, TTM)
- -6.3
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 0 | -5,8 mi | -7 mi | |
| 0 | -10,8 mi | -11,5 mi | |
| 0 | -10,5 mi | -10,1 mi | |
| 0 | -13,2 mi | -13,2 mi |